PET imaging of amyloid-beta (Aβ) deposits in brain has become an important aid in Alzheimer's
disease diagnosis, and an inclusion criterion for patient enrolment into clinical trials of …

Antibodies are highly specific for their target molecules, but their poor brain penetrance has
restricted their use as PET ligands for imaging of targets within the CNS. The aim of this …

Visualization of amyloid-β (Aβ) pathology with PET has become an important tool for making
a specific clinical diagnosis of Alzheimer disease (AD). However, the available amyloid PET …

Monoclonal antibodies (mAbs) have not been used as positron emission tomography (PET)
ligands for in vivo imaging of the brain because of their limited passage across the blood-…

PET imaging of amyloid-β (Aβ) has become an important component of Alzheimer disease
diagnosis. C-Pittsburgh compound B ( 11 C-PiB) and analogs bind to fibrillar Aβ. However, …

Purpose The triggering receptor expressed on myeloid cells 2 (TREM2) is expressed by
brain microglia. Microglial activation, as observed in Alzheimer’s disease (AD) as well as in …

One of the major hallmarks of Alzheimer’s disease (AD) pathology is the formation of
extracellular amyloid β (Aβ) plaques. While Aβ has been suggested to be critical in inducing and, …

Amyloid-β (Aβ) oligomers and protofibrils are suggested to be the most neurotoxic Aβ species
in Alzheimer's disease (AD). Hence, antibodies with strong and selective binding to these …

Positron emission tomography (PET), a medical imaging technique allowing for studies of
the living human brain, has gained an important role in clinical trials of novel drugs against …

Purpose Antibody-based constructs, engineered to enter the brain using transferrin receptor
(TfR) mediated transcytosis, have been successfully used as PET radioligands for imaging …